Lunai Bioworks Inc. - Common Stock (LNAI)

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

A new wave of activity across biotech innovation, artificial intelligence, digital infrastructure, and global manufacturing is drawing increased investor attention as several emerging growth companies report significant developments that could shape their next phase of expansion.

Lunai Bioworks (Nasdaq: LNAI ) is an AI-enabled biotechnology company advancing rapid in vivo phenotypic drug discovery across CNS and biodefense applications. By integrating high-throughput vertebrate screening with machine learning analytics, LNAI seeks to accelerate therapeutic discovery while reducing cost, time, and capital intensity.

Full Alliance Group (OTCQB: FAGI) continues executing its multi-vertical growth strategy as its subsidiary Aquaox Pure Solutions, LLC reports accelerating marketplace traction for JusSpray™, the company’s flagship hypochlorous acid (HOCl) skin defense spray.

Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.